S
TLX

SignatureFD’s Telix Pharmaceuticals TLX Stock Holding History

SignatureFD’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.71K Buy
+148
New +$1.51K ﹤0.01% 3164

Other funds holding TLX

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
AP
Aspect Partners Fairfax, Virginia $268M AUM 22.57% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
BWL
Bogart Wealth LLC Mclean, Virginia $2.92B AUM 23.85% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

SignatureFD's TLX Position: Q2 2026 in Review

SignatureFD opened a new position in Telix Pharmaceuticals (TLX) in Q2 2026: 148 shares worth $1.71K. The stake represents ﹤0.01% of the portfolio and ranks #3164 among its holdings.

9 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • SignatureFD held 148 shares of Telix Pharmaceuticals worth $1.71K as of Q2 2026.
  • Telix Pharmaceuticals was a new SignatureFD position in Q2 2026.
  • Telix Pharmaceuticals made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #3164 holding.
  • 9 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.